Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer

Toshihiko Sumii, Akihiro Funakoshi, Tetsuhide Ito, Kazuhiro Mizumoto, Masao Tanaka, Yoshikatsu Migita, Terufumi Sakai, Hirotsugu Shinozaki, Hiroya Yamaguchi, Toshihiko Niyahara, Toru Muranaka, Naofumi Eriguchi, Toshiharu Ueki

Research output: Contribution to journalArticlepeer-review


Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan. No complete remissions, 5 partial remissions (10%) and 25 no changes (51%) were obtained. Gemcitabine could maintain QOL. Main toxicities were hematologic, especially neutropenia. Neutropenia tended to appear in early administration. Non-hematologic toxicities were anorexia, nausea/vomiting, and skin rash. The mean overall survival period was 7.5 months. Carcinomatous ascites and/or pleural effusion resulted in a poor prognosis (average survival 3.1 months). Gemcitabine could be given without severe toxicities in outpatient clinics. These results suggested that gemcitabine is currently a first-line therapeutic agent for advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)971-976
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number7
Publication statusPublished - Jul 2003

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this